Mihai D, Voiculescu S, Dimitriu C, Constantinescu F, Stanilescu S, Burcos T
Surgery Clinic, "Coltea" Hospital, Bucharest.
J Med Life. 2014;7 Spec No. 2(Spec Iss 2):58-64.
Aggressive breast cancer is an invasive form with a differentiation degree G3/G4, the absence of estrogen receptor and progesterone and the absence or presence of the gene HER 2(+ or 3+). The immunohistochemical tests have an important role in establishing the diagnosis and the therapy.
It was shown that the aggressive breast cancers, 97 out of 316 cases were operated in the period October 2011 - February 2014. The criteria of inclusion/ exclusion in the study groups and the treatment schemes were exposed.
For the study group (group A=43/ group B=45/ group C=9 cases), the distribution according to the age group and immunohistochemical classification, were shown and, histologically, the type of surgical intervention, postoperative staging, postoperative complications were highlighted.
The treatment of the aggressive forms of breast cancer, neoadjuvant and adjuvant can both be set only by IHC tests.
侵袭性乳腺癌是一种分化程度为G3/G4的浸润性癌，雌激素受体和孕激素均缺失，HER 2基因缺失或存在（2+或3+）。免疫组织化学检测在诊断和治疗中具有重要作用。
结果表明，在2011年10月至2014年2月期间，对316例侵袭性乳腺癌患者中的97例进行了手术。阐述了研究组的纳入/排除标准及治疗方案。
对于研究组（A组=43例/B组=45例/C组=9例），展示了按年龄组和免疫组织化学分类的分布情况，并从组织学角度突出了手术干预类型、术后分期及术后并发症。
侵袭性乳腺癌的治疗，无论是新辅助治疗还是辅助治疗，都只能通过免疫组织化学检测来确定。
